Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is expected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $62.01 million for the quarter.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same period in the prior year, the business earned ($1.21) EPS. On average, analysts expect Keros Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $13.76 on Wednesday. The business’s fifty day moving average price is $12.05 and its 200-day moving average price is $25.42. Keros Therapeutics has a one year low of $9.12 and a one year high of $72.37. The stock has a market capitalization of $558.81 million, a PE ratio of -2.64 and a beta of 1.32.

Insider Activity at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the company’s stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now directly owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of recent research reports. Oppenheimer reduced their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday, January 16th. Wedbush reiterated a “neutral” rating and set a $15.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, April 1st. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Truist Financial decreased their price target on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. Finally, Piper Sandler cut their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.